Skip to content

Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture

Temperature Telemonitoring for Hospital at Home (HaH) Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05959928
Acronym
Viture
Enrollment
208
Registered
2023-07-25
Start date
2021-02-09
Completion date
2021-06-02
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacteremia, Cellulitis, COVID-19, Infectious Disease, Respiratory Infection, Tract Infection, Urinary

Keywords

Continuous body temperature monitoring, Hospital at Home, Telemonitoring, Remote Patient Monitoring, Virtual wards, Fever detection, Infectious diseases, Telemedicine, Telehealth, COVID-19, Real-time data

Brief summary

The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer. The study also aims to evaluate the safety and comfort of the system and to evaluate the impact that the introduction of Viture has on the health care practice of a HaH unit. Furthermore, the advantages of Viture compared to the standard method will be evaluated.

Detailed description

Body temperature is a key vital sign in the follow-up of patients admitted to Hospital at Home (HaH) units with COVID-19 and other infectious diseases. Continuous telemonitoring of temperature can lead to earlier detection of fever and patient deterioration that facilitates early decision making. In the first day of the study, the patients will be given a study kit of Viture System with the following content: * Viture Device. * Digital reference thermometer for control Spot Temperature Measurements (STMs) * Smartphone with Viture Mobile App installed. * Device user manual in quick guide format. * Home data collection notebook (HDCN) The HaH team will place Viture Device on the patient and train the patient and/or caregiver. They will ask patients to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the HDCN. In the case that the bracelet is removed, or the patient experience discomfort, they will be asked to fill in the incident in the HDCN. Mild incidents are considered skin alterations such as redness and chafing and severe incidents are considered hematomas and ulcers. The HaH team on duty will collect all Viture notifications, registering the date, time, and follow-up for each febrile episode. The patient and/or caregiver could be contacted to request a control STM. A statistical analysis of agreement between the digital reference thermometer (Gold standard) and Viture will be carried out. The non-parametric Wilcoxon signed rank test will be used to evaluate the average agreement between the two methods, and the Bland Altman method will be used to evaluate the agreement between individual measurements. Both analyses will be validated with a 95% confidence interval. To explore the true potential of Viture, an analysis of the febrile episodes experienced by patients during the clinical study will be performed. Febrile episodes will be characterized by their maximum temperature and duration. To assess the impact of Viture notifications, the data registered on the follow-up of febrile episodes will be analyzed.

Interventions

DEVICEContinuous wearable thermometer placed on patient's armpit to monitor body temperature remotely

The HaH team will place Viture Device on the patient's armpit and train the patient and/or caregiver. They will ask to complete control STMs between 3 and 6 times a day on the same arm where the Viture Device is placed and record the measuring data in the Home data collection notebook (HDCN)

Sponsors

Hospital of Navarra
CollaboratorOTHER
NavarraBiomed Biomedical Research Center
CollaboratorOTHER
Vitio Medical S.L.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* be more than 18 years old. * to be able to legally give informed consent. * not to have limitations to the use of the Viture Device due to their physical conditions or interference with other devices.

Exclusion criteria

* To be monitored for less than 2 days. * To have less than 4 valid control Spot Temperature Measurements (STM). A valid control STM is considered a temperature measured with the reference thermometer that has a simultaneous (within 1 minute) Viture Temperature Measurement (VTM)

Design outcomes

Primary

MeasureTime frameDescription
Verify that, under normal conditions of use, the performance of Viture for body temperature measurement is equivalent to the devices used in the standard practice.3 measurements per dayComparison between the temperatures recorded remotely by Viture and a control digital thermometer used in the follow-up of patients in Hospital at Home, both COVID-19 patients and patients with other diseases who benefit from body temperature monitoring.

Secondary

MeasureTime frameDescription
Evaluate the safety, usability and comfort of Viture DeviceThrough study completion, an average of 5 daysRecord usability experience and negative sensations expressed by users due to the use of Viture, such as discomfort or skin irritation in the area where the device is placed.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026